To evaluate the associations of preoperative De Ritis ratio (aspartate transaminase [AST]/alanine transaminase [ALT]) with postoperative clinical outcomes after surgical treatment of localized RCC.
Introduction
In both men and women, RCC is one of the most common cancers and is the most commonly diagnosed malignancy among renal tumours [1] . Owing to modern advanced radiological screening tools such as CT and ultrasonography, the incidence of renal tumours has been steadily increasing during the last decade, which has resulted in a corresponding increase in the incidence of RCC [2] . To date, the 'gold standard' curative therapy for RCC has been surgical resection [3] , therefore, it is becoming more clinically important to identify the prognostic indicators of postoperative survival in patients with localized RCC.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are well-known liver enzymes produced by both malignant and non-malignant cells. They have been previously reported to be significant prognostic biomarkers in several malignancies such as lung, colonic, pancreatic and breast cancer [4] [5] [6] [7] . Moreover, the De Ritis ratio (AST/ALT ratio) has been widely used in the evaluation of various causes of liver disease. Previously, Bezan et al. [8] reported that the AST/ALT ratio can predict postoperative survival outcomes in patients with localized RCC after surgery. In their study, patients with a high AST/ALT ratio had inferior survival outcomes in terms of overall survival (OS) and progression-free survival (PFS). Although their study was valuable for presenting the AST/ALT ratio as a novel prognostic factor, they were not able to evaluate cancerspecific survival (CSS) and only analysed a small number of patients.
The aim of the present study was to evaluate the true prognostic value of AST/ALT ratio in patients surgically treated for localized RCC in our relatively large cohort using propensity score matching analysis.
Materials and Methods
After approval by our institutional ethical review board, we retrospectively reviewed the records of 3 162 patients surgically treated for localized RCC from January 2006 to June 2013 in two tertiary centres in South Korea. After the additional exclusion of 197 patients (for other malignancy [n = 46], chronic hepatitis [n = 89], liver cirrhosis [n = 21], and incomplete information [n = 41]), we finally included 2 965 patients. Clinical and pathological data were retrieved from the prospectively maintained databases of both institutions. Abdominal CT, chest radiography (or CT), and bone scan were included in the routine preoperative evaluation. The pathological staging and histological subtyping were decided according to the Union for International Cancer Control seventh TNM classification, the American Joint Committee on Cancer guidelines, and the Heidelberg recommendations [9, 10] . Cellular grading was performed using Fuhrman's grading system [11] . Disease progression was identified on radiological or pathological evidence of local recurrence, distant metastasis or mortalities from RCC. Postoperative evaluations were performed in our outpatient clinic at 3-to 6-month intervals for the first 2 years and yearly thereafter. Mortality data were acquired from the database of the Korean National Statistical Office and by reviewing our medical records. PFS, CSS and OS rates were determined at the last follow-up date using the date of surgery to the date of progression, any-cause mortality, or cancer-specific mortality, respectively.
To determine the optimum threshold for AST/ALT ratio, the receiver-operating curve of AST/ALT for cancer-specific mortality was analysed. As an AST/ALT ratio of 1.5 had maximum Youden index value, the threshold for AST/ALT was set at 1.5; therefore, patients with an AST/ALT ratio ≥1.5 were assigned to the high AST/ALT group, while the remaining patients (AST/ALT < 1.5) were assigned to the low AST/ALT group. There were 437 patients in the high AST/ ALT group and 2 528 patients in the low AST/ALT group. As there were significant differences among patients in several preoperative characteristics, we matched them based on the propensity to have a high AST/ALT ratio. The propensity scores were estimated using non-parsimonious multivariate logistic regression according to preoperative characteristics such as age, gender, body mass index (BMI), Eastern Cooperative Oncology Group score, symptoms at diagnosis, tumour size, surgical approach (radical vs partial nephrectomy) and history of hypertension. Postoperative characteristics, such as pathological stage and Fuhrman grade, were excluded from propensity score matching because these variables could not be involved in the determination of the preoperative condition. After excluding seven patients without appropriate pairs, 430 patients with a high AST/ALT ratio were matched to 1 117 patients with a low AST/ALT ratio in a 1:3 ratio using the nearest-neighbour method, with a calibre of 0.02. When we assessed the balance of baseline covariates between the groups, we found that our propensity score model was well calibrated and discriminating, with all standardized mean differences <0.05 (Table 1) .
Independent t-tests and chi-squared tests were used to evaluate the differences in peri-operative characteristics between the subgroups. Logistic regression tests were performed for univariate and multivariate analyses for adverse pathological events. Kaplan-Meier analysis with log-rank tests were performed to evaluate the difference in survival outcomes between AST/ALT subgroups. Multivariate Coxproportional hazard analysis was performed to identify the predictors of survival outcomes after surgery. All statistical analyses were performed using SPSS software package (SPSS 19.0, Chicago, IL, USA). All P values were two-sided and a P value < 0.05 was taken to indicate statistical significance.
Results
The clinical characteristics of all patients are summarized in Table 1 . The patient's median (interquartile range [IQR]) age was 55.0 (47-65) years, their median (IQR) AST/ALT ratio was 1.0 (0.8-1.3) and the median (IQR) follow-up time was 37.0 (24-73) months. With regard to the clinical characteristics of the two groups, patients in the high AST/ ALT group were significantly older (P < 0.001), were predominantly men (P < 0.001), had higher BMI (P < 0.001), more likely to have a positive history of hypertension (P = 0.046), had larger tumour volume (P < 0.001), were more likely to have symptomatic disease at diagnosis (P < 0.001), and were more likely to be treated by radical nephrectomy (P < 0.001) compared with patients with low AST/ALT. The high AST/ALT group had worse pathological features than the low AST/ALT group, as evidenced by significantly higher pathological stage (P < 0.001) and cellular grade (P = 0.023), 
Survival Outcomes
Before propensity score matching After a median (IQR) of 23 (8-40) months postoperatively, 271 patients had disease progression. There were 96 cancerspecific deaths after a median (IQR) of 37 (11-64.8) months, and 156 overall deaths after a median (IQR) of 37 (14-64.8) months postoperatively. Kaplan-Meier analysis showed significantly inferior PFS (P < 0.001), OS (P < 0.001), and CSS rates (P < 0.001) in the high AST/ALT ratio group (Fig. 1) . A high preoperative AST/ALT ratio was found to be a significant independent predictor of PFS (hazard ratio [HR] 1.461; 95% CI 1.084-1.968; P = 0.017), OS (HR 1.770; 95% CI 1.238-2.531; P = 0.002) and CSS (HR 2.346; 95% CI 1.513-3.637; P < 0.001) from multivariate Cox analyses (Table 2 ). Subsequently, the prognostic value of AST/ALT ratio was tested separately in each subgroup according to RCC histological subtype. When we performed Kaplan-Meier analysis in 2 474 RCC patients with clear-cell type histology, we observed significantly inferior PFS (P < 0.001), OS (P < 0.001) and CSS (P < 0.001) outcomes in the high AST/ALT group. Multivariate Cox analysis also showed that high preoperative AST/ALT ratio was an independent predictor of PFS (HR 1.553; 95% CI 1.129-2.137; P = 0.007), OS (HR 1.904; 95% CI 1.294-2.802; P = 0.001) and CSS (HR 2.769, 95% CI 1.740-4.406; P < 0.001 [ Table 2 ]). KaplanMeier analysis of the survival data for the 491 patients with non-clear-cell type RCC showed a significant difference in OS (P = 0.019) but not in PFS (P = 0.062) or CSS (P = 0.115) between the high and low AST/ALT groups. The subsequent multivariate analysis did not find any significant associations of AST/ALT ratio with any of the three survival endpoints (all P > 0.4; Table 2 ).
After propensity score matching
At a median (IQR) of 37.5 (19.3-80.8) months postoperatively, 172 patients had disease progression. There were 78 cancer-specific deaths after a median (IQR) of 29 (11-60) months and 116 deaths from all causes after a median (IQR) of 33 (13-63) months postoperatively. The high AST/ALT group also had significantly inferior survival outcomes in terms of PFS, OS and CSS in the propensity score-matched cohort (all P < 0.001; Fig. 1 ). High AST/ALT was found to be an independent predictor of PFS (HR 1.372, 95% CI 1.003-1.882; P = 0.048), OS (HR 1.559, 95% CI 1.069-2.272; P = 0.021) and CSS (HR 1.974, 95% CI 1.250-3.118; P = 0.004) in multivariate Cox proportional analyses (Table 3) . On performing Kaplan-Meier analysis separately in each tumour histology subgroup, the high AST/ALT group had significantly inferior PFS (P = 0.015), OS (P < 0.001) and CSS outcomes (P < 0.001) in the clearcell type subgroup, whereas no significant survival differences were observed in the non-clear-cell type subgroup (all P > 0.1). A high AST/ALT ratio was also found to be a significant predictor of PFS (HR 1.531, 95% CI 1.088-2.154; P = 0.015), OS (HR 1.720, 95% CI 1.141-2.594; P = 0.010) and CSS (HR 2.411, 95% CI 1.478-3.933; P < 0.001) in the clear-cell subgroup, but not in the nonclear-cell subgroup (all P > 0.7; Table 2 ).
Discussion
In the present study, patients with a high AST/ALT ratio were found to have significantly worse clinical outcomes in terms of PFS, OS and CSS after analysing our relatively large cohort of 2 965 patients surgically treated for non-metastatic RCC. A high AST/ALT ratio was independently associated with PFS, OS and CSS after surgery. To minimize bias from possible confounding preoperative factors that may be related to AST/ALT, a propensity score-matched analysis was performed. In the matched cohort of 1 547 patients, the aforementioned findings persisted for all three survival endpoints.
Serum AST and ALT levels are well known useful biomarkers widely used to determine liver function in clinical care, and to identify liver disease such as viral hepatitis and alcohol abuse. While ALT is found predominantly only in the liver, AST is widely distributed in several organs such as the liver, heart, skeletal muscle, kidney and brain [12] ; therefore, ALT specifically indicates liver disease, whereas AST is connected with several diseases affecting other organs. De Ritis et al. [13] were the first to introduce the AST/ALT ratio as a useful indicator for differentiating the aetiology of acute hepatitis, and previous studies have reported AST and ALT to be significant prognostic factors in various malignancies such as the lung, colonic and pancreatic cancer [4] [5] [6] [7] . Rawson and Peto [5] retrospectively analysed 3 873 patients with smallcell lung cancer and reported that AST was a significant ALT, alanine transaminase; AST aspartate transaminase; BMI, Body mass index; CSS, cancer-specific survival; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
© 2016 The Authors BJU International © 2016 BJU International 265 prognostic factor. Lindmark et al. [4] also reported that AST and ALT were significantly associated with patients' survival after analysing 212 patients with colorectal cancer. Stocken et al. analysed the data of 653 patients with advanced pancreatic cancer from two randomized studies, and also concluded that AST was independently related to CSS [6] . In a recent study, Thornburg et al. [7] tried to inhibit lactate dehydrogenase and AST function to suppress the metabolism and proliferation of breast cancer cells. They found no impairment of lactate production, but definite anti-metabolic effects were produced from AST inhibition in terms of decreased oxygen consumption and decreased NADH/NAD + ratio. They also observed suppressed proliferation of breast cancer cells from inhibition of AST.
The prognostic effects of AST/ALT in localized RCC were first introduced by Bezan et al. [8] . They performed a retrospective analysis of 698 patients with non-metastatic RCC after surgery and reported AST/ALT ratio to be a significant predictive factor for metastasis-free survival (HR 1.61, 95% CI 1.25-2.07; P < 0.001) and OS (HR 1.76, 95% CI 1.34-2.32; P < 0.001), which was in line with our results. Although their study was limited by the small number of patients, and the lack of analysis of the impact of AST/ALT on CSS, it was valuable for introducing the novel prognostic impact of AST/ALT for the first time. To the best of our knowledge, there are no other studies focusing on the prognostic impact of AST/ALT in patients with RCC.
It is known that RCC comprises a completely heterogeneous group of various subtypes arising from different cellular origins in the kidney [14] . Valenca et al. [15] insisted that the relatively low incidence of non-clear-cell RCC subtypes resulted in a lack of studies devoted to each distinct RCC subtype. Patard et al. [16] stratified 4 063 patients with localized RCC into three subgroups according to their histological subtypes and reported significant differences in 5-year CSS according to tumour histology. Another study by Cheville et al. also found a significant difference in CSS according to histological tumour subtype after retrospectively analysing 2 385 patients surgically treated for RCC [17] . Along with those prognostic and morphological differences, there have been efforts to subdivide the conventional RCC subtypes according to genomic characteristics [18] . In the present study, we also tried to evaluate the prognostic impact of AST/ALT separately according to the histological subtype of RCC. It is notable that patients with clear-cell histology had significantly inferior survival outcomes in the high AST/ ALT group, while there was no significant difference in any of the three survival endpoints in patients with non-clear-cell histology in the propensity score-matched cohort. AST/ALT ratio may therefore have a prognostic significance in patients with clear-cell type RCC but not in non-clear-cell RCC. The exact mechanism behind the association between clear-cell RCC and AST/ALT ratio remains obscure and requires further investigation. A possible hypothesis for this phenomenon might lie in the differences in genomic alterations between RCC subtypes such as the von HippelLindau gene (VHL). VHL is known to be the most frequent mutation in clear-cell type RCC, with an incidence ranging from 70 to 90% [19, 20] . Moreover, VHL has various regulatory effects such as tumour suppression, and regulation of certain angiogenic factors such as vascular endothelial growth factor-1, and transforming growth factor. Shiao et al. [21] analysed the subcellular localization of VHL using cytoplasmic immunostaining, and concluded that it was frequently found in the cytoplasm of mitochondria in clearcell type RCC. They also hypothesized that carcinogenesis by VHL might occur through mitochondria-based actions. More importantly, mitochondria play an essential role in glucose and lipid metabolism. VHL loss is also known to induce hypoxia-induced factor expression, which is connected to extensively increased glycolysis, known as Warburg's effect [22] . Recently, lactate dehydrogenase and a high NADH/ NAD + ratio were proposed to have a crucial role in maintaining glucose catabolism [23] . Moreover, AST is known to have a vital role in glycolysis by relocation of NADH into mitochondria through the malate-aspartate shuttle pathway [24] . It is highly likely, therefore, that AST and ALT are involved in the glycolysis mechanism in clearcell type RCC with VHL loss, but our understanding of these exact mechanisms is so far limited.
The present study has some limitations. As the AST/ALT ratio showed limited prognostic significance only in the clearcell type RCC, it should not be used in non-clear-cell type RCC or without any histological confirmation. Even with further evidence from future investigations, its utility may be confined only to risk stratification after histological confirmation and not in the determination of treatment. In addition, the retrospective nature of the present study may have led to an inherent structural bias, and the follow-up period was relatively short. Patients with disease progression underwent different salvage therapies with respect to timing and treating clinicians. These different salvage therapies may have influenced the different survival outcomes. Finally, our study population consisted of Korean patients only, and it should be validated before applying the results to other racial groups.
In conclusion, an elevated preoperative AST/ALT ratio was found to be a significant prognostic factor for postoperative survival in patients with localized RCC. Because the subgroup analyses according to RCC histological subtype showed a significant association only in clear-cell type RCC, it should be noted that its prognostic value is limited only to the clearcell type RCC. Further studies are needed to identify the exact mechanisms underlying the impact of AST/ALT on the outcome of RCC.
